Quarterly report · Q2
2112.TEDINET S100PGCP
Period2022-04-01 → 2022-09-30
Filed2022-11-04
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥13.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥25.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥274m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥454m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥244m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥906m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥389m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥244m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥389m | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥138m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥609m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥233m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥138m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥233m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥25.2bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥26.1bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥26.7bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.8bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥15.7bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥10.4bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥10.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.0bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.3bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥104m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥210m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥172m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥711m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥482m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥948m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥5.1 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.14 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.43 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.61 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.55 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 41.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.5% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-04-01 → 2022-09-30 | ¥67m |
| Otherother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥59m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥8m |
| Otherother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥30m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥55m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥55m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥577m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥925m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥891m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥34m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥238m |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥13m |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥582m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥13.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥13.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥55m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥851m |
| Otherother segments | revenue | 2021-04-01 → 2021-09-30 | ¥66m |
| Otherother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥58m |
| Otherother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8m |
| Otherother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥30m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥50m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥50m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥586m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥939m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥910m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥28m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥264m |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥11.3bn |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥11.3bn |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥14m |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥745m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥12.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥12.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥50m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 493
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 11290000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 939000000 | JPY |
| Net sales | Prior1YTDDuration_OtherReportableSegmentsMember | 66000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 12296000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -50000000 | JPY |
| Net sales | Prior1YTDDuration | 12246000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 745000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 264000000 | JPY |
| Operating income | Prior1YTDDuration_OtherReportableSegmentsMember | 30000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1040000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -586000000 | JPY |
| Operating income | Prior1YTDDuration | 454000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 12434000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 891000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OtherReportableSegmentsMember | 59000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 13384000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 13384000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 13000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 34000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OtherReportableSegmentsMember | 8000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 55000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -55000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 12448000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 925000000 | JPY |
| Net sales | CurrentYTDDuration_OtherReportableSegmentsMember | 67000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 13440000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -55000000 | JPY |
| Net sales | CurrentYTDDuration | 13384000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 582000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 238000000 | JPY |
| Operating income | CurrentYTDDuration_OtherReportableSegmentsMember | 30000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 851000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -577000000 | JPY |
| Operating income | CurrentYTDDuration | 274000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-04 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第90期第２四半期(自 2022年７月１日 至 2022年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)塩水港精糖株式会社 | |
| Company name in english cover page | FilingDateInstant | Ensuiko Sugar Refining Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役会長兼社長 久 野 修 慈 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋堀留町二丁目９番６号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京(03)3249-2381(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)常務取締役 小 田 俊 一 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋堀留町二丁目９番６号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京(03)3249-2381(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)常務取締役 小 田 俊 一 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |